Insider Selling: Francis Reynolds Sells 36,000 Shares of Invivo Therapeutics Holdings Corp Stock (NVIV)
Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) major shareholder Francis Reynolds sold 36,000 shares of the company’s stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $1.43, for a total transaction of $51,480.00. Following the sale, the insider now directly owns 11,427,920 shares in the company. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
A number of research firms have recently commented on NVIV. Analysts at Zacks reiterated a “neutral” rating on shares of Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) in a research note to investors on Tuesday, August 27th. They now have a $2.00 price target on the stock. Analysts at Aegis raised their price target on shares of Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) from $6.00 to $7.00 in a research note to investors on Friday, August 23rd. They now have a “buy” rating on the stock.
Shares of Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) traded up 0.71% on Wednesday, hitting $1.41. The stock had a trading volume of 359,393 shares. Invivo Therapeutics Holdings Corp has a 1-year low of $0.94 and a 1-year high of $6.20. The stock has a 50-day moving average of $3.10 and a 200-day moving average of $3.33. The company’s market cap is $110.8 million.
InVivo Therapeutics Holdings Corp., formerly Design Source, Inc is a development-stage company. The Company is developing and commercializing technologies for the treatment of spinal cord injuries.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.